The stock of Quest Diagnostics Incorporated (NYSE: DGX) has decreased by -0.61 when compared to last closing price of 128.13. Despite this, the company has experienced a 0.19% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-09-14 that Quest Diagnostics (DGX) and Americares will provide 10 clinics with no-cost diagnostic services for a year to help patients manage chronic disease.
Is It Worth Investing in Quest Diagnostics Incorporated (NYSE: DGX) Right Now?
The price-to-earnings ratio for Quest Diagnostics Incorporated (NYSE: DGX) is above average at 18.56x, while the 36-month beta value is 0.94.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 16 as “hold,” and 0 as “sell.”
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free
The average price point forecasted by analysts for Quest Diagnostics Incorporated (DGX) is $147.50, which is $20.15 above the current market price. The public float for DGX is 111.29M, and currently, short sellers hold a 2.64% ratio of that floaft. The average trading volume of DGX on September 15, 2023 was 808.90K shares.
DGX’s Market Performance
The stock of Quest Diagnostics Incorporated (DGX) has seen a 0.19% increase in the past week, with a -4.63% drop in the past month, and a -6.53% fall in the past quarter. The volatility ratio for the week is 1.40%, and the volatility levels for the past 30 days are at 1.41% for DGX. The simple moving average for the last 20 days is -2.58% for DGX stock, with a simple moving average of -9.39% for the last 200 days.
DGX Trading at -5.81% from the 50-Day Moving Average
After a stumble in the market that brought DGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.57% of loss for the given period.
Volatility was left at 1.41%, however, over the last 30 days, the volatility rate increased by 1.40%, as shares sank -3.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.85% lower at present.
During the last 5 trading sessions, DGX rose by +0.19%, which changed the moving average for the period of 200-days by -14.56% in comparison to the 20-day moving average, which settled at $130.48. In addition, Quest Diagnostics Incorporated saw -18.59% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DGX starting from Doherty Catherine T., who sale 5,307 shares at the price of $140.55 back on Mar 07. After this action, Doherty Catherine T. now owns 67,810 shares of Quest Diagnostics Incorporated, valued at $745,899 using the latest closing price.
PREVOZNIK MICHAEL E, the SVP & General Counsel of Quest Diagnostics Incorporated, sale 4,754 shares at $140.55 during a trade that took place back on Mar 07, which means that PREVOZNIK MICHAEL E is holding 38,527 shares at $668,175 based on the most recent closing price.
Stock Fundamentals for DGX
Current profitability levels for the company are sitting at:
- +16.41 for the present operating margin
- +33.87 for the gross margin
The net margin for Quest Diagnostics Incorporated stands at +9.53. The total capital return value is set at 14.71, while invested capital returns managed to touch 8.84. Equity return is now at value 12.90, with 6.00 for asset returns.
Based on Quest Diagnostics Incorporated (DGX), the company’s capital structure generated 79.99 points at debt to equity in total, while total debt to capital is 44.44. Total debt to assets is 36.72, with long-term debt to equity ratio resting at 75.80. Finally, the long-term debt to capital ratio is 42.11.
When we switch over and look at the enterprise to sales, we see a ratio of 1.98, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 7.51 and the total asset turnover is 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.22.
Conclusion
In a nutshell, Quest Diagnostics Incorporated (DGX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
